AGPCNP NURS6203
Advanced Pharmacology
4.0 Credits
Final Exam Review (Qns & Ans)
2025
©2025
,**1.*
**Case:* A 68-year-old male with refractory ventricular arrhythmias is
enrolled in a clinical trial of a novel antiarrhythmic agent that selectively
inhibits the late sodium current.
**Question:* What is the primary pharmacologic effect of inhibiting the
late sodium current in the failing myocardium?
A. Prolongation of the repolarization phase
B. Reduction of intracellular calcium overload through decreased
sodium–calcium exchanger activity
C. Increased conduction velocity by enhancing depolarization
D. Direct inhibition of potassium channels
**Correct ANS:* **B*
**Rationale:* Inhibition of the late sodium current reduces intracellular
sodium concentration, which in turn decreases calcium influx via the
sodium–calcium exchanger. This limits calcium overload, improves
diastolic function, and reduces myocardial oxygen consumption.
---
**2.*
**Case:* A new antipsychotic agent shows high affinity for both
dopamine D2 and serotonin 5-HT2A receptors.
**Question:* What is the clinical significance of this dual receptor
binding profile?
A. It increases the risk of metabolic syndrome.
B. It minimizes extrapyramidal side effects by offsetting dopamine
blockade.
C. It leads to pronounced sedation without mood improvement.
D. It results in rapid receptor desensitization.
**Correct ANS:* **B*
**Rationale:* The blockade of 5-HT2A receptors can help mitigate
dopaminergic blockade in the nigrostriatal pathway, reducing the
incidence of extrapyramidal symptoms—a common adverse effect of
©2025
, pure D2 antagonism.
---
**3.*
**Case:* An AGPCNP evaluates a newly approved oral anticoagulant that
selectively inhibits factor Xa.
**Question:* Which advantage does selective factor Xa inhibition
provide compared with traditional vitamin K antagonists?
A. Wide therapeutic index with no need for monitoring
B. A more predictable pharmacokinetic profile and fewer dietary
interactions
C. Direct inhibition of the coagulation cascade at multiple points
D. Greater reversal potential in the event of bleeding
**Correct ANS:* **B*
**Rationale:* Factor Xa inhibitors boast predictable pharmacokinetics
and minimal dietary interactions, reducing the need for frequent
monitoring while maintaining effective anticoagulation.
---
**4.*
**Case:* A novel antidiabetic drug acts as an agonist at the peroxisome
proliferator-activated receptor‑γ (PPAR‑γ).
**Question:* Which metabolic effect is most commonly associated with
PPAR‑γ activation?
A. Increased hepatic gluconeogenesis
B. Enhanced peripheral glucose uptake and improved insulin sensitivity
C. Direct stimulation of pancreatic β‑cell insulin secretion
D. Suppression of adiponectin levels
**Correct ANS:* **B*
**Rationale:* PPAR‑γ agonists improve insulin sensitivity in peripheral
tissues and facilitate glucose uptake, a critical mechanism in managing
type 2 diabetes.
©2025
Advanced Pharmacology
4.0 Credits
Final Exam Review (Qns & Ans)
2025
©2025
,**1.*
**Case:* A 68-year-old male with refractory ventricular arrhythmias is
enrolled in a clinical trial of a novel antiarrhythmic agent that selectively
inhibits the late sodium current.
**Question:* What is the primary pharmacologic effect of inhibiting the
late sodium current in the failing myocardium?
A. Prolongation of the repolarization phase
B. Reduction of intracellular calcium overload through decreased
sodium–calcium exchanger activity
C. Increased conduction velocity by enhancing depolarization
D. Direct inhibition of potassium channels
**Correct ANS:* **B*
**Rationale:* Inhibition of the late sodium current reduces intracellular
sodium concentration, which in turn decreases calcium influx via the
sodium–calcium exchanger. This limits calcium overload, improves
diastolic function, and reduces myocardial oxygen consumption.
---
**2.*
**Case:* A new antipsychotic agent shows high affinity for both
dopamine D2 and serotonin 5-HT2A receptors.
**Question:* What is the clinical significance of this dual receptor
binding profile?
A. It increases the risk of metabolic syndrome.
B. It minimizes extrapyramidal side effects by offsetting dopamine
blockade.
C. It leads to pronounced sedation without mood improvement.
D. It results in rapid receptor desensitization.
**Correct ANS:* **B*
**Rationale:* The blockade of 5-HT2A receptors can help mitigate
dopaminergic blockade in the nigrostriatal pathway, reducing the
incidence of extrapyramidal symptoms—a common adverse effect of
©2025
, pure D2 antagonism.
---
**3.*
**Case:* An AGPCNP evaluates a newly approved oral anticoagulant that
selectively inhibits factor Xa.
**Question:* Which advantage does selective factor Xa inhibition
provide compared with traditional vitamin K antagonists?
A. Wide therapeutic index with no need for monitoring
B. A more predictable pharmacokinetic profile and fewer dietary
interactions
C. Direct inhibition of the coagulation cascade at multiple points
D. Greater reversal potential in the event of bleeding
**Correct ANS:* **B*
**Rationale:* Factor Xa inhibitors boast predictable pharmacokinetics
and minimal dietary interactions, reducing the need for frequent
monitoring while maintaining effective anticoagulation.
---
**4.*
**Case:* A novel antidiabetic drug acts as an agonist at the peroxisome
proliferator-activated receptor‑γ (PPAR‑γ).
**Question:* Which metabolic effect is most commonly associated with
PPAR‑γ activation?
A. Increased hepatic gluconeogenesis
B. Enhanced peripheral glucose uptake and improved insulin sensitivity
C. Direct stimulation of pancreatic β‑cell insulin secretion
D. Suppression of adiponectin levels
**Correct ANS:* **B*
**Rationale:* PPAR‑γ agonists improve insulin sensitivity in peripheral
tissues and facilitate glucose uptake, a critical mechanism in managing
type 2 diabetes.
©2025
